In vitro susceptibilities of Zygomycota to polyenes

被引:15
作者
Dannaoui, E
Meis, JFGM
Mouton, JW
Verweij, PE
机构
[1] Univ Med Ctr St Radboud, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[2] Canisius Wilhelmina Hosp, NL-65000 GS Nijmegen, Netherlands
关键词
D O I
10.1093/jac/dkf012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activity of polyenes was determined for 36 isolates of Zygomycota including Rhizopus spp. (15), Absidia corymbifera (10), Mucor spp. (6), Rhizomucor spp. (3), Cunninghamella bertholletiae (1) and Apophysomyces elegans (1). All isolates were tested with amphotericin B, heated amphotericin B and nystatin by a broth microdilution test. There were no significant differences between heated and unheated solutions of amphotericin B in terms of their antifungal activities. The MICs of amphotericin B for most of the strains were <2 mg/L. For all isolates, nystatin was significantly less active than amphotericin B (P < 0.001). The one C. bertholletiae and one A. elegans isolates were less susceptible to amphotericin B (MICs 2 mg/L) and were also less susceptible to nystatin.
引用
收藏
页码:741 / 744
页数:4
相关论文
共 11 条
[1]   Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B [J].
Denning, DW ;
Warn, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2592-2599
[2]   Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index [J].
Gaboriau, F ;
Cheron, M ;
Petit, C ;
Bolard, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2345-2351
[3]   Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics [J].
Groll, AH ;
Gonzalez, CE ;
Giri, N ;
Kligys, K ;
Love, W ;
Peter, J ;
Feuerstein, E ;
Bacher, J ;
Piscitelli, SC ;
Walsh, TJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :95-103
[4]   Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations [J].
Johnson, EM ;
Ojwang, JO ;
Szekely, A ;
Wallace, TL ;
Warnock, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1412-1416
[5]   SEVERE OSTEOMYELITIS DUE TO THE ZYGOMYCETE APOPHYSOMYCES ELEGANS [J].
MEIS, JFGM ;
KULLBERG, BJ ;
PRUSZCZYNSKI, M ;
VETH, RPH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (12) :3078-3081
[6]  
National Committee for Clinical Laboratory Standards, 1998, M38P NAT COMM CLIN L
[7]   Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole [J].
Oakley, KL ;
Moore, CB ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1264-1266
[8]   In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating [J].
Petit, C ;
Chéron, M ;
Joly, V ;
Rodrigues, JM ;
Bolard, J ;
Gaboriau, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :779-785
[9]   Zygomycetes in human disease [J].
Ribes, JA ;
Vanover-Sams, CL ;
Baker, DJ .
CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (02) :236-+
[10]   Mild heating of amphotericin B-desoxycholate: Effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice [J].
van Etten, EWM ;
van Vianen, W ;
Roovers, P ;
Frederik, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1598-1603